Mastodon

Star-Pen (Granules) Instructions for Use

Marketing Authorization Holder

Sandoz, GmbH (Austria)

ATC Code

J01CE02 (Phenoxymethylpenicillin)

Active Substance

Phenoxymethylpenicillin (Rec.INN registered by WHO)

Dosage Form

Bottle Rx Icon Star-Pen Granules for the preparation of an oral suspension 400 thousand IU/5 ml: bottle 60 ml

Dosage Form, Packaging, and Composition

Granules for the preparation of an oral suspension 5 ml of prepared susp.
Phenoxymethylpenicillin potassium 400000 IU

4800000 IU – Dark glass bottles with a volume of 60 ml (1) – cardboard packs.

Clinical-Pharmacological Group

Penicillin antibiotic, destroyed by penicillinase

Pharmacotherapeutic Group

Antibiotic, penicillin

Pharmacological Action

An antibiotic from the group of biosynthetic penicillins. The mechanism of action is associated with the inhibition of bacterial cell wall synthesis. It acts bactericidally. Acid-resistant.

Active against aerobic gram-positive bacteria: Staphylococcus spp., Streptococcus spp. (including Streptococcus pneumoniae), Enterococcus spp. (some strains), Clostridium spp., Corynebacterium spp., Erysipelothrix rhusiopathiae, Listeria spp., Bacillus anthracis, Actinomyces spp.; aerobic gram-negative bacteria: Neisseria meningitidis, Neisseria gonorrhoeae; Pasteurella multocida, Streptobacillus spp.; anaerobic bacteria: Peptococcus spp., Peptostreptococcus spp., Fusobacterium spp., Clostridium spp.

Also active against Spirullinum minus, Treponema pallidum, Borrelia spp., Leptospira interrogans.

Staphylococcus spp. (strains producing penicillinase) are resistant to phenoxymethylpenicillin.

Pharmacokinetics

Phenoxymethylpenicillin is acid-resistant, not destroyed in the acidic environment of the stomach. Absorption in the alkaline environment of the small intestine is 30-60%. Plasma protein binding is 60-80%. Cmax is reached 30-60 minutes after administration. Phenoxymethylpenicillin penetrates into the kidneys, liver, skin, lungs, mucous membrane, muscles, wall of the small intestine and into most body fluids, especially in the presence of inflammatory processes; lower concentrations are determined in bone tissue. It crosses the placental barrier and is found in small amounts in breast milk. About 30-35% is metabolized in the liver. T1/2 is 30-60 minutes. It is excreted mainly by the kidneys unchanged (25%) and in the form of metabolites (35%); about 30% is excreted through the gastrointestinal tract.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to phenoxymethylpenicillin, including bronchitis, pneumonia, tonsillitis, scarlet fever, otitis media, gonorrhea, syphilis, tetanus, anthrax, purulent diseases of the skin and soft tissues.

For prophylaxis: wounds of various etiologies (including bites); burns; prevention of streptococcal infections and their complications (including rheumatism /rheumatic attack, chorea minor/, polyarthritis, glomerulonephritis, endocarditis); prevention of bacterial endocarditis in patients with congenital or acquired rheumatic heart defects before and after minor surgical interventions (tonsillectomy, tooth extraction); prevention of pneumococcal pneumonia in children with sickle cell anemia; prevention of rheumatism exacerbations.

ICD codes

ICD-10 code Indication
A22 Anthrax
A35 Other forms of tetanus
A38 Scarlet fever
A51 Early syphilis
A52 Late syphilis
A54 Gonococcal infection
H66 Suppurative and unspecified otitis media
I00 Rheumatic fever without mention of heart involvement
I01 Rheumatic fever with heart involvement
I02 Rheumatic chorea
I33 Acute and subacute endocarditis
J03 Acute tonsillitis
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J42 Unspecified chronic bronchitis
L01 Impetigo
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L08.0 Pyoderma
L08.8 Other specified local infections of skin and subcutaneous tissue
M05 Seropositive rheumatoid arthritis
M13.9 Arthritis, unspecified
M15 Polyosteoarthritis
N00 Acute nephritic syndrome (acute glomerulonephritis)
N03 Chronic nephritic syndrome
N51 Disorders of male genital organs in diseases classified elsewhere
N74.3 Gonococcal inflammatory diseases of female pelvic organs
T14.0 Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect)
T14.1 Open wound of unspecified body region
T30 Burns and corrosions of unspecified body region
T79.3 Posttraumatic wound infection, not elsewhere classified
Z29.2 Other prophylactic chemotherapy (administration of antibiotics for prophylactic purposes)
ICD-11 code Indication
1A61.Z Early syphilis, unspecified
1A62.Z Late syphilis, unspecified
1A7Z Gonococcal infection, unspecified
1B40.0 Rheumatic arthritis, acute or subacute
1B40.Z Acute rheumatic fever without mention of heart involvement, unspecified
1B41.Z Acute rheumatic heart disease, unspecified
1B42 Rheumatic chorea
1B50 Scarlet fever
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B72.0 Bullous impetigo
1B72.1 Nonbullous impetigo
1B72.Z Impetigo, unspecified
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1B7Y Other specified pyogenic bacterial infections of skin or subcutaneous tissue
1B97 Anthrax
1C13 Tetanus
1C44 Non-pyogenic bacterial infections of skin
AA9Z Unspecified suppurative otitis media
BB4Z Acute or subacute endocarditis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA20.1Z Chronic bronchitis, unspecified
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
EA50.3 Staphylococcal scarlet fever
EB21 Pyoderma gangrenosum
EH92 Dermatoses provoked by friction or mechanical impact
EH92.1 Blister due to friction
FA05 Polyosteoarthritis
FA20.0 Seropositive rheumatoid arthritis
FA2Z Inflammatory arthropathies, unspecified
GB06.0Z Unspecified balanoposthitis
GB0Z Diseases of male genital system, unspecified
GB40 Nephritic syndrome
ND56.0 Superficial injury of unspecified body region
ND56.1 Open wound of unspecified body region
NE11 Burn of unspecified body region
NF0A.3 Posttraumatic wound infection, not elsewhere classified
QC05.Y Other specified prophylactic measures
1A71 Gonococcal pelviperitonitis
GA05.Z Inflammatory diseases of female pelvic organs, unspecified
1B40.Y Other specified acute rheumatic fever without mention of heart involvement
CA40.08 Pneumonia due to Beta-haemolytic streptococcus
GB40 Nephritic syndrome
XT8W Chronic course

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Individual. For moderate infections, adults and children over 10 years old – 3 million IU/day. For severe infections, the dose is increased to 6-9 million IU/day. For children under 10 years of age – 50,000-100,000 IU/kg/day. Frequency of administration – 3-6 times/day. The course of treatment is on average at least 5-7 days; when treating infections caused by β-hemolytic streptococcus – at least 7-10 days.

Adverse Reactions

Allergic reactions infrequently – urticaria, skin hyperemia, angioedema, rhinitis, conjunctivitis; rarely – fever, serum sickness, arthralgia, eosinophilia; very rarely – anaphylactic shock.

From the hematopoietic system rarely – hemolytic anemia, leukopenia, agranulocytosis, thrombocytopenia, pancytopenia.

From the digestive system infrequently – nausea, vomiting, diarrhea, glossitis, stomatitis, vesicular cheilitis, decreased appetite, dry mouth, taste disturbance; rarely – pseudomembranous colitis.

Other rarely – interstitial nephritis, vasculitis.

Contraindications

Hypersensitivity to phenoxymethylpenicillin and other beta-lactam antibiotics (penicillins, cephalosporins, carbapenems); severe course of infections (including the acute stage of severe pneumonia); gastrointestinal diseases accompanied by vomiting and diarrhea; aphthous stomatitis and pharyngitis; gastroparesis, cardia spasm or increased intestinal motility; children’s age – depending on the dosage form.

With caution

In allergic diseases (bronchial asthma, hay fever, diathesis), allergic reactions (in history).

Use in Pregnancy and Lactation

During pregnancy, it is possible to use according to indications in cases where the intended benefit to the mother outweighs the potential risk to the fetus. If it is necessary to use during lactation, the issue of stopping breastfeeding should be decided.

Pediatric Use

It is possible to use in children according to indications, in doses and dosage forms recommended according to age. It is necessary to strictly follow the instructions in the instructions for phenoxymethylpenicillin preparations regarding contraindications for the use of specific dosage forms of phenoxymethylpenicillin in children of different ages.

Special Precautions

If allergic reactions develop, Phenoxymethylpenicillin should be discontinued and appropriate therapy prescribed.

The use of phenoxymethylpenicillin in combination with bacteriostatic antibiotics should be avoided. Combination with other antibiotics is allowed if an additive or synergistic effect is expected.

During long-term treatment, the possibility of growth of resistant strains of bacteria and fungi should be taken into account.

In case of persistent diarrhea, the possibility of developing pseudomembranous colitis should be considered.

With prolonged use, periodic monitoring of the peripheral blood picture and indicators of liver and kidney function is recommended.

When using phenoxymethylpenicillin, false-positive results are possible in the reaction during non-enzymatic determination of glucose in urine and in the analysis for urobilinogen and the results of quantitative determination of amino acids in urine by the ninhydrin method.

Effect on the ability to drive vehicles and mechanisms

During the use of phenoxymethylpenicillin, patients should be careful when driving vehicles and mechanisms, as well as when engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

With simultaneous use, Phenoxymethylpenicillin increases the effectiveness of indirect anticoagulants (by suppressing the intestinal microflora, it reduces the formation of vitamin K); reduces the effectiveness of oral contraceptives and drugs in the process of metabolism of which para-aminobenzoic acid is formed.

With simultaneous use, Phenoxymethylpenicillin increases the risk of “breakthrough” bleeding while taking ethinyl estradiol.

With simultaneous use, antacids, glucosamine, laxatives, aminoglycosides and food slow down and reduce the absorption of phenoxymethylpenicillin; ascorbic acid increases it.

With simultaneous use of bactericidal antibiotics (including cephalosporins, cycloserine, vancomycin, rifampicin), aminoglycosides, synergism of action is observed; with simultaneous use of bacteriostatic antibiotics (including macrolides, chloramphenicol, lincosamides, tetracyclines) – antagonism.

With simultaneous use, diuretics, allopurinol, phenylbutazone, NSAIDs and other drugs that reduce tubular secretion increase the concentration of phenoxymethylpenicillin and enhance its effect.

With simultaneous use of phenoxymethylpenicillin and allopurinol, the risk of developing allergic reactions (skin rash) increases.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS